Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.82 USD
-0.02 (-0.52%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AQST 3.82 -0.02(-0.52%)
Will AQST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Other News for AQST
Commit To Buy Aquestive Therapeutics At $2.50, Earn 32.4% Annualized Using Options
Aquestive Therapeutics (AQST) Appoints New Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer
Aquestive's Anaphylm to be reviewed by Health Canada